Asset Details
Do you wish to reserve the book?
Cannabinoids go nuclear: evidence for activation of peroxisome proliferator‐activated receptors
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Cannabinoids go nuclear: evidence for activation of peroxisome proliferator‐activated receptors
Do you wish to request the book?
Cannabinoids go nuclear: evidence for activation of peroxisome proliferator‐activated receptors
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Cannabinoids go nuclear: evidence for activation of peroxisome proliferator‐activated receptors
2007
Overview
Cannabinoids act at two classical cannabinoid receptors (CB1 and CB2), a 7TM orphan receptor and the transmitter‐gated channel transient receptor potential vanilloid type‐1 receptor. Recent evidence also points to cannabinoids acting at members of the nuclear receptor family, peroxisome proliferator‐activated receptors (PPARs, with three subtypes α, β (δ) and γ), which regulate cell differentiation and lipid metabolism. Much evidence now suggests that endocannabinoids are natural activators of PPARα. Oleoylethanolamide regulates feeding and body weight, stimulates fat utilization and has neuroprotective effects mediated through activation of PPARα. Similarly, palmitoylethanolamide regulates feeding and lipid metabolism and has anti‐inflammatory properties mediated by PPARα. Other endocannabinoids that activate PPARα include anandamide, virodhamine and noladin. Some (but not all) endocannabinoids also activate PPARγ; anandamide and 2‐arachidonoylglycerol have anti‐inflammatory properties mediated by PPARγ. Similarly, ajulemic acid, a structural analogue of a metabolite of Δ9‐tetrahydrocannabinol (THC), causes anti‐inflammatory effects in vivo through PPARγ. THC also activates PPARγ, leading to a time‐dependent vasorelaxation in isolated arteries. Other cannabinoids which activate PPARγ include N‐arachidonoyl‐dopamine, HU210, WIN55212‐2 and CP55940. In contrast, little research has been carried out on the effects of cannabinoids at PPARδ. In this newly emerging area, a number of research questions remain unanswered; for example, why do cannabinoids activate some isoforms and not others? How much of the chronic effects of cannabinoids are through activation of nuclear receptors? And importantly, do cannabinoids confer the same neuro‐ and cardioprotective benefits as other PPARα and PPARγ agonists? This review will summarize the published literature implicating cannabinoid‐mediated PPAR effects and discuss the implications thereof.
British Journal of Pharmacology (2007) 152, 576–582; doi:10.1038/sj.bjp.0707423; published online 20 August 2007
Publisher
Blackwell Publishing Ltd,Nature Publishing Group
